Bill > S625

This bill aims to eliminate out-of-pocket expenses for patients receiving COVID-19 therapeutics covered under their health care service plan or disability insurance policy. It requires health care service plans to cover the full cost of COVID-19 therapeutics approved or granted emergency use authorization by the FDA, without any cost-sharing or utilization management requirements. The bill also sets guidelines for reimbursing providers, including out-of-network providers, to ensure they accept the negotiated or reasonable rates as payment in full and cannot seek additional remuneration from patients. The provisions related to MassHealth managed care plans are contingent on obtaining necessary federal approvals. Overall, the bill seeks to improve access to COVID-19 treatments by making them more affordable for patients.

Business and Industry

https://malegislature.gov/Bills/193/S625